Exagen Inc. (XGN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Exagen Inc. (XGN) trades at $4.68 with AI Score 20/100 (Grade F). Exagen Inc. focuses on developing and commercializing diagnostic testing products for autoimmune diseases. Market cap: $113M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 9, 2026Analyst Coverage for XGN: XGN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates XGN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
XGN: 3/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Exagen Inc. (XGN) Healthcare & Pipeline Overview
Exagen Inc. pioneers diagnostic solutions for autoimmune diseases, leveraging its AVISE technology to provide rheumatologists with tools for improved diagnosis and patient management. With a focus on connective tissue diseases, Exagen addresses a critical need in the healthcare sector, though profitability remains a challenge.
What Is the Investment Thesis for XGN?
Exagen Inc. presents a focused investment opportunity within the autoimmune diagnostics space. The company's AVISE branded tests cater to a critical need for rheumatologists, offering tools for diagnosing and monitoring complex conditions like lupus and rheumatoid arthritis. With a gross margin of 58.3%, Exagen demonstrates strong pricing power. Growth catalysts include expanding the adoption of AVISE CTD and other specialized tests, as well as potential breakthroughs from their research collaboration with Allegheny Health Network (AHN). However, the company's negative profit margin of -30.0% and high beta of 1.94 indicate significant financial risk and market volatility. Investors should closely monitor Exagen's ability to improve profitability and manage its operating expenses.
Based on FMP financials and quantitative analysis
XGN Key Highlights
- Market Cap of $113M reflects its small-cap status and potential for growth, but also higher volatility.
- Gross Margin of 58.3% indicates strong pricing power in its diagnostic testing services.
- Profit Margin of -30.0% highlights the company's current unprofitability and need for improved cost management.
- Beta of 1.94 suggests the stock is significantly more volatile than the overall market.
- Focus on autoimmune disease diagnostics positions Exagen in a growing market with unmet needs.
Who Are XGN's Competitors?
XGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LH Labcorp Holdings Inc. | $281.48 | -0.66% | $23.1B | 70 |
| DGX Quest Diagnostics Incorporated | $207.66 | -1.43% | $23.0B | 74 |
| CORBF Global Cord Blood Corporation | $0.95 | +0.00% | $127M | 53 |
| GTH Genetron Holdings Limited | $4.03 | +0.12% | $127M | 61 |
| DIUXF Diaceutics PLC | $2.00 | +0.00% | $169M | 59 |
| THOXF BioPorto A/S | $0.15 | +0.00% | $73.8M | 55 |
| BIOGF Biocartis Group N.V. | $0.66 | -85.33% | $65.4M | 52 |
| PFGTF Pacific Edge Limited | $0.17 | +0.00% | $212M | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XGN's Key Strengths?
- Proprietary CB-CAPs technology
- AVISE branded tests with established clinical utility
- Focus on specialized diagnostic testing for autoimmune diseases
- Research collaboration with Allegheny Health Network (AHN) Research Institute
What Are XGN's Weaknesses?
- Negative profit margin
- High beta indicating significant market volatility
- Reliance on a limited number of products
- Small market capitalization
What Could Drive XGN Stock Higher?
- Data releases from ongoing clinical studies evaluating the clinical utility of AVISE tests.
- Potential FDA approvals for new diagnostic tests developed in collaboration with AHN.
- Expansion of sales and marketing efforts to increase adoption of AVISE CTD and other specialized tests.
- Securing favorable reimbursement decisions from payers for AVISE branded tests.
What Are the Key Risks for XGN?
- Financial-distress signal — its Altman Z-Score of -5.86 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from established diagnostic companies with greater resources.
- Reimbursement challenges and changes in healthcare policies.
- Failure to successfully develop and commercialize new diagnostic tests.
- Dependence on a limited number of products and customers.
What Are the Growth Opportunities for XGN?
- Expanding AVISE CTD Adoption: AVISE CTD is Exagen's lead testing product, offering differential diagnosis for connective tissue diseases. Increasing its adoption among rheumatologists represents a significant growth opportunity. The market for CTD diagnostics is substantial, driven by the complexity of these diseases and the need for accurate and timely diagnosis. Exagen can expand its market share through targeted marketing, educational programs, and partnerships with healthcare providers. Success hinges on demonstrating the clinical utility and cost-effectiveness of AVISE CTD.
- Commercializing AVISE Lupus and APS: AVISE Lupus and AVISE APS address the diagnostic and management needs for systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), respectively. These tests offer valuable insights into disease activity and potential complications. The market for SLE and APS diagnostics is growing, driven by increasing awareness and improved treatment options. Exagen can capitalize on this trend by expanding its sales force, conducting clinical studies, and securing favorable reimbursement for these tests. Success depends on demonstrating the clinical value and cost-effectiveness of AVISE Lupus and APS.
- Developing Novel Biomarkers: Exagen's research collaboration with Allegheny Health Network (AHN) Research Institute focuses on developing novel biomarkers for autoimmune diseases. This collaboration has the potential to yield breakthrough diagnostic and prognostic tools. The market for novel biomarkers is substantial, driven by the need for more precise and personalized medicine. Exagen can leverage this collaboration to expand its product portfolio and gain a competitive advantage. Success depends on the successful identification, validation, and commercialization of these biomarkers.
- Expanding into New Geographic Markets: Exagen currently focuses on the United States market. Expanding into new geographic markets, such as Europe and Asia, represents a significant growth opportunity. The global market for autoimmune disease diagnostics is substantial, driven by increasing prevalence and improved healthcare infrastructure. Exagen can leverage its existing technology and expertise to enter these markets through partnerships, acquisitions, or direct sales. Success depends on adapting its products and marketing strategies to local market conditions.
- Securing Favorable Reimbursement: Reimbursement policies play a critical role in the adoption of diagnostic tests. Securing favorable reimbursement for its AVISE branded tests is essential for Exagen's growth. The market for reimbursed diagnostic tests is substantial, driven by the need for affordable and accessible healthcare. Exagen can work with payers, healthcare providers, and patient advocacy groups to demonstrate the clinical value and cost-effectiveness of its tests. Success depends on navigating the complex reimbursement landscape and securing favorable coverage decisions.
What Opportunities Does XGN Have?
- Expanding AVISE CTD adoption
- Commercializing AVISE Lupus and APS
- Developing novel biomarkers
- Expanding into new geographic markets
What Threats Does XGN Face?
- Competition from established diagnostic companies
- Reimbursement challenges
- Regulatory changes
- Technological obsolescence
What Are XGN's Competitive Advantages?
- Proprietary CB-CAPs technology
- AVISE branded tests with established clinical utility
- Research collaboration with Allegheny Health Network (AHN) Research Institute
- Focus on specialized diagnostic testing for autoimmune diseases
What Does XGN Do?
Exagen Inc., founded in 2002 and headquartered in Vista, California, is a diagnostics company focused on autoimmune diseases. Originally named Exagen Diagnostics, Inc., the company rebranded in January 2019 to Exagen Inc. The company develops and commercializes testing products based on its cell-bound complement activation products (CB-CAPs) technology under the AVISE brand. These tests enable rheumatologists to diagnose, prognose, and monitor autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Exagen's lead product, AVISE CTD, aids in the differential diagnosis of patients presenting with symptoms indicative of various connective tissue diseases (CTDs). Other key offerings include AVISE Lupus, which measures complement system activation, and AVISE APS, a panel of autoantibody tests for diagnosing and managing antiphospholipid syndrome (APS). The company also provides specialized tests like AVISE SLE Prognostic, AVISE Vasculitis AAV, AVISE Anti-CarP, AVISE PC4d, AVISE SLE Monitor, AVISE MTX, and AVISE HCQ. Exagen collaborates with Allegheny Health Network (AHN) Research Institute to develop novel biomarkers, enhancing its diagnostic capabilities.
What Products and Services Does XGN Offer?
- Develop and commercialize diagnostic testing products.
- Focus on autoimmune and autoimmune-related diseases.
- Offer AVISE CTD for differential diagnosis of connective tissue diseases.
- Provide AVISE Lupus for measuring complement system activation.
- Offer AVISE APS for diagnosing and managing antiphospholipid syndrome.
- Develop specialized tests like AVISE SLE Prognostic and AVISE Vasculitis AAV.
- Collaborate with Allegheny Health Network (AHN) Research Institute to develop novel biomarkers.
How Does XGN Make Money?
- Generate revenue through the sale of diagnostic testing services.
- Focus on direct sales to rheumatologists and healthcare providers.
- Secure reimbursement from payers for its AVISE branded tests.
- Collaborate with research institutions to develop new products and technologies.
What Industry Does XGN Operate In?
Exagen Inc. operates within the medical diagnostics and research industry, a segment experiencing growth driven by increasing prevalence of autoimmune diseases and advancements in diagnostic technologies. The market is competitive, with established players and emerging companies vying for market share. Exagen differentiates itself through its CB-CAPs technology and specialized AVISE tests. The industry is also influenced by regulatory requirements, reimbursement policies, and technological innovations. Exagen's success depends on its ability to innovate, secure favorable reimbursement, and effectively market its diagnostic solutions to rheumatologists and healthcare providers.
Who Are XGN's Key Customers?
- Rheumatologists
- Healthcare providers
- Patients with autoimmune diseases
- Hospitals and clinics
Key Financial Metrics
Return on assets is -38.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.3%, the inverse of the P/E and a quick read on earnings relative to price.
How Exagen Inc. Is Valued
Exagen Inc. carries a market capitalization of $113M, placing it in the micro-cap category. Relative to its peer group, XGN's quantitative score of 20/100 is below the peer average of 63/100.
F-Score 3/9Financial Health
Exagen Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.86 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Exagen Inc. revenue of about $71.6M for fiscal 2026, with EPS near $-0.69. The estimate reflects 5 contributing analysts.
XGN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Exagen's future performance, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively as discussions around the company's innovative diagnostic solutions gain traction among investors.
- Exagen's focus on autoimmune diseases aligns with increasing demand for specialized healthcare solutions, enhancing its market appeal.
- Recent partnerships in the healthcare sector have improved Exagen's visibility, fostering optimism about its growth prospects.
Bear Case
- Concerns over regulatory approvals for new products have created uncertainty among investors, leading to cautious sentiment in the community.
- Recent earnings reports have raised questions about profitability, causing some traders to reassess their positions on Exagen.
- Market perception remains mixed as competition in the diagnostic space intensifies, potentially impacting Exagen's market share.
- Social media discussions reflect a level of skepticism regarding the sustainability of Exagen's growth, with some investors expressing doubt about long-term viability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
XGN Latest News
No recent news available for XGN.
XGN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for XGN.
Price Targets
Wall Street price target analysis for XGN.
XGN MoonshotScore
What does this score mean?
The MoonshotScore rates XGN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: John Aballi
CEO
John Aballi serves as the CEO of Exagen Inc., leading the company's strategic direction and operational execution. His background includes extensive experience in the healthcare and diagnostics industries. Prior to joining Exagen, Aballi held leadership positions at various healthcare companies, where he focused on driving growth, innovation, and market expansion. He brings a wealth of knowledge in commercialization, product development, and business strategy to Exagen.
Track Record: Since becoming CEO, John Aballi has focused on expanding the adoption of Exagen's AVISE branded tests and driving revenue growth. He has also overseen the company's research collaboration with Allegheny Health Network (AHN) Research Institute to develop novel biomarkers. Under his leadership, Exagen has continued to innovate and expand its product portfolio.
Exagen Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for XGN?
XGN holds an AI Score of 20/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Exagen Inc. focuses on developing and commercializing diagnostic testing products for autoimmune diseases. Their AVISE branded tests assist rheumatologists in diagnosing, prognosing, and monitoring …
What does Exagen Inc. do?
Exagen Inc. is a commercial-stage diagnostics company focused on developing and marketing innovative testing solutions for autoimmune diseases. The company's AVISE branded tests help rheumatologists diagnose, prognose, and monitor complex conditions like lupus, rheumatoid arthritis, and other connective tissue diseases. Exagen's proprietary CB-CAPs technology provides unique insights into disease activity and potential complications, enabling more informed treatment decisions.
What do analysts say about XGN stock?
Analyst coverage of Exagen Inc. (XGN) is limited, reflecting its small-cap status. Generally, analysts focus on the company's revenue growth potential, driven by increased adoption of its AVISE branded tests. Key valuation metrics include price-to-sales ratio and enterprise value-to-revenue multiple. Growth considerations include the company's ability to secure favorable reimbursement, expand its product portfolio, and manage its operating expenses.
What are the main risks for XGN?
Exagen Inc. faces several key risks, including competition from larger, more established diagnostic companies, reimbursement challenges and changes in healthcare policies, and the potential failure to successfully develop and commercialize new diagnostic tests. The company's dependence on a limited number of products and customers also poses a risk. Additionally, Exagen's high beta indicates significant market volatility. Investors should carefully consider these risks before investing in XGN.
What are the key factors to evaluate for XGN?
Exagen Inc. (XGN) holds an AI score of 20/100 (low). Not financial advice.
How frequently does XGN data refresh on this page?
XGN's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven XGN's recent stock price performance?
Exagen Inc. (XGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary CB-CAPs technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XGN overvalued or undervalued right now?
Exagen Inc. (XGN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research XGN before investing?
Before investing in Exagen Inc. (XGN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-09.
- Financial data may be subject to change.